Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 4;9:602. doi: 10.3389/fonc.2019.00602

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Yu, Wang, Kaul, Wadhwa and Miyako.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

In vivo anticancer effect of FRi-ExNC on enhancing selective targeting of FR-α-expressing tumors. Relative HeLa (A) and HT-29 (B) tumor volumes in different groups of mice during the course of treatment (mean ± s.e.m., n = 5), ^***P <0.001 (two-way ANOVA test). Subcutaneous xenografts of HeLa (FR+) cells in nude mice treated with FRi-ExNC showed low tumor-forming capacity as compared to HT-29 (FR-) cells. (C) Inhibition rate of HeLa and HT-29 xenografts in nude mice with different treatments at the end of the experiment (mean ± s.e.m., n = 5), ^*P <0.05 (Student's t-test). The data indicates that FRi-ExNC has the selectivity to impede HeLa (FR+) tumor progression. (D) The average body weight of mice did not show any loss during treatments. All the treatments were performed with an equivalent dose of i-Ex (50 mg/Kg/2 days).